Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06586281 · ClinicalTrials.gov registry record · NA

Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy

A NA study of Psoriatic Arthritis, sponsored by University of California, San Diego.

Recruiting
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT06586281 is a NA study of Psoriatic Arthritis that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 20 participants, below the 852-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06586281, a NA study of Psoriatic Arthritis, is actively recruiting participants, sponsored by University of California, San Diego.

RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

While many studies examine Nonalcoholic fatty liver disease (NAFLD), little is known about its progression to high-risk nonalcoholic steatohepatitis (NASH) in PsA patients. Shared disease mechanisms may explain the increased severity in PsA. This study involves two visits from PsA patients with NAFLD and active disease signs (e.g., swollen joint, enthesitis, or psoriatic plaque). It aims to assess the impact of biological therapies on liver disorders, joints, and skin in PsA patients.

Conditions Studied

Interventions

  • DRUG Guselkumab

Study Locations (1)

California

  • University of California, San Diego - San Diego

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2025-06-01
Est. Completion 2026-12-01
Phase NA

Sponsor

University of California, San Diego

775 total trials

What the Registry Record Tells You About NCT06586281

The ClinicalTrials.gov registry entry for NCT06586281 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 852-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (98% lower). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Psoriatic Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Guselkumab is the first listed.

NCT06586281 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06586281 about?

NCT06586281 is a clinical study titled "Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy". While many studies examine Nonalcoholic fatty liver disease (NAFLD), little is known about its progression to high-risk nonalcoholic steatohepatitis (NASH) in PsA patients. Shared disease mechanisms may explain the increased severity in PsA. This study involves two visits from PsA patients with NAFL...

What is the current status of trial NCT06586281?

This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2025-06-01. Estimated completion is 2026-12-01.

What conditions does trial NCT06586281 study?

This clinical trial studies the following conditions: Psoriatic Arthritis.

What interventions are being tested in trial NCT06586281?

The interventions under investigation include: Guselkumab (DRUG).

Who is sponsoring clinical trial NCT06586281?

This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06586281 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Psoriatic Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.